Peptidream earnings date
Want to see JP:4587 full AI Analyst Report?
Peptidream (4587) Q4 2025 Earnings Report
JP:4587 Q4 2025 EPS Results
- Actual EPS
- -JPY 4.11
- Consensus EPS
- -JPY 5.70
- Beat/Miss
- Beat by +JPY 1.59
- One Year Ago EPS
- -JPY 20.10
JP:4587 Q4 2025 Revenue Results
- Actual Revenue
- JPY 5.66B
- Expected Revenue
- JPY 6.00B
- Beat/Miss
- Missed by -JPY 334.92M
- YoY Revenue Growth
- +11.66%
Earnings Announcement Details
- Quarter
- Q4 2025
- Date
- 02/16/2026
- Time
- TBA
- Conference Call
- Monday, February 16, 2026
Peptidream's next earnings date is estimated for February 17, 2027, based on past reporting schedules.
Q4 2025 Earnings Call Audio
Q4 2025 Earnings Slide Deck
Q4 2025 Earnings Call Summary
The call presented substantial operational and pipeline progress — notably strong clinical momentum (6 programs entering clinic in 2025, 13 total clinical programs), late-stage radiopharmaceutical programs with NDA timelines, IND acceptances and a healthy cash balance (JPY 28.6 billion). At the same time, key revenue drivers were delayed (notably the myostatin out‑licensing), R&D and headcount-driven costs are increasing (R&D +28% year-over-year; headcount +6.4%), and several high-value deals remain timing-uncertain. Overall, the company appears to be transitioning from a discovery-focused model to a discovery-and-development company with meaningful upside from pipeline advances, but near-term financial performance depends on timing of large upfront deals and execution of planned manufacturing expansions.
PeptiDream's FY2026 guidance calls for consolidated revenue of JPY 32.0 billion plus additional outsourcing/upfront payments (management referenced a potential upfront of ~JPY 14.0 billion), expects 6–12 programs to enter clinical development in 2026 and to close the year with 19–25 clinical programs (up from 13 at end‑2025 after six clinic entries in 2025), budgets R&D to increase to JPY 6.4 billion (from JPY 5.0 billion in FY2025), and notes cash of JPY 28.6 billion at end‑2025; the group’s headcount rose to ~810 (from 761), total 2025 costs (COGS+SG&A) were about JPY 23.5 billion, the company remains net‑cash positive with an improving equity ratio and no planned equity financing, and it is progressing capital projects (Tonomachi HQ construction now targeted for early 2027; Kazusa manufacturing to start late‑2026 and become operational in 2028).
- Strong Clinical Momentum — 2025Six programs entered clinical development in FY2025, bringing the total to 13 clinical programs (an addition of 6 programs in the year). In total, 13 programs staged advanced across the portfolio during 2025.
- Late-Stage Radiopharmaceuticals with NDA TimelinesPDRadiopharma has three late-stage programs on a regulatory path: Copper-64-ATSM (Phase III, malignant brain tumors) targeting NDA submission in 2027; Gallium-64 PSMA-I&T diagnostic (first patients dosed, on path for 2027 NDA); and 177-Lutetium PSMA I&T therapeutic registrational bridging study on path toward potential submission in 2029.
- In-house IND Filings and Upcoming Phase I StartsINDs for in-house CAXI diagnostic (Copper-64) and therapeutic (Actinium-225) were accepted at end of 2025, with Phase I start planned in 2026. Additional in-house programs (CAIX, cadherin-3) progressed into IND-enabling or planning early human validation studies.
- Revenue Guidance and Cash PositionManagement guided FY2026 revenue around JPY 32 billion (plus expected lump-sum/upfront receipts discussed on the call). Consolidated cash position at end-December 2025 was JPY 28.6 billion and the company remains net cash positive with an improving equity ratio.
- PDRadiopharma Growth and Manufacturing Expansion PlansPDRadiopharma positioned as Japan's radiopharmaceutical leader (450+ employees) with planned Kazusa manufacturing site construction starting late 2026 and expected operational capability around 2028 to support Lu-177, Ac-225 and Cu-64 programs.
- Platform and Scientific BreakthroughsKey scientific progress included a reported large-animal demonstration (with Alnylam) of extrahepatic, tissue-specific delivery for peptide-oligonucleotide conjugates and successful in vivo proof-of-concept for in-house immune-engager MPCs, strengthening multiple core therapeutic area approaches.
- Ambitious Clinical Pipeline Outlook for 2026Management expects 6–12 additional programs to enter clinical development in 2026, with an end-2026 target of ~19–25 clinical programs (roughly balanced between RI and non-RI).
- Maintained Profitability and Conservative Financial DisciplineCompany emphasized four consecutive years of profitability post-merger, maintained net cash positive status, improving equity ratio, and a conservative FY2026 forecast designed to avoid repeating 2025 over-optimism.
JP:4587 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 17, 2027 | 2026 (Q4) | 46.77- | -4.11 | ― | ― |
| Nov 11, 2026 | 2026 (Q3) | -7.01-2.84 | -8.48 | 66.51% (+5.64) | |
| Aug 12, 2026 | 2026 (Q2) | -3.19-8.89 | -8.43 | -5.46% (-0.46) | |
| May 13, 2026 | 2026 (Q1) | -8.05-6.62 | -7.97 | 16.94% (+1.35) | |
| Feb 16, 2026 | 2025 (Q4) | -5.70-4.11 | -20.1 | 79.55% (+15.99) | |
| Nov 12, 2025 | 2025 (Q3) | -7.58-8.48 | -2.35 | -260.85% (-6.13) | |
| Aug 06, 2025 | 2025 (Q2) | 10.19-8.43 | 144.8 | -105.82% (-153.23) | |
| May 13, 2025 | 2025 (Q1) | -4.57-7.97 | -6.5 | -22.62% (-1.47) | |
| Feb 13, 2025 | 2024 (Q4) | -8.88-20.10 | -3.89 | -416.71% (-16.21) | |
| Nov 13, 2024 | 2024 (Q3) | 3.08-2.35 | 32.92 | -107.14% (-35.27) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

